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Endothelial cells (EC)' can function as APCs (1-4) and, as the lining cells of
the vasculature, are uniquely positioned to use antigen presentation as a means
of selectively recruiting those circulating T cells specific for an eliciting antigen
into a site of developing immune inflammation (5). Since T cells can only
recognize antigen presented in association with MHC molecules (6), the quanti-
tative level ofMHC molecule expression on the surface ofa presenting cell is a
determinant of antigen-presenting capacity (7, 8) . EC expression ofMHC mole-
cules, as for many other cell types, is regulated by cytokines . Under standard
culture conditions, human umbilical vein-derived EC express class I but not class
II MHC antigens (9) . Previous studies from our laboratory (10-13) as well as
from others (14, 15) have shown that leukocyte IFN-a and fibroblast IFN-,0
increase expression of class I antigens on EC without inducing class II antigens,
whereas immune IFN-y both increases class I and leads to de novo expression of
class II molecules (HLA-DR > HLA-DP > HLA-DQ) . In EC, MHC antigen
expression is, at least in part, controlled by steady-state mRNA levels . IFN-a,
IFN-#, and IFN-y treatment led to increased levels of class I transcripts ; only
IFN-y led to the de novo appearance of the heavy and light chain transcripts for
the three class II molecules as well as for the non-MHC-encoded invariant chain
(12) . Subsequent studies from our laboratory (16, 17) revealed that TNF and,
more recently, that lymphotoxin (LT) as well, act like IFN-a/fl by increasing
both steady-statemRNA levels and surface expression ofclass I molecules without
inducing class II transcripts or surface expression . Although functionally indis-
tinguishable in these assays, we found that TNF differed from IFN-a/# at the
level of mechanism, in that the protein synthesis inhibitor cycloheximide led to
enhancement of the IFN-ai-mediated increase of class I mRNA levels (and
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revealed induction of class 11 mRNA), whereas this agent blocked the actions of
TNF (16); cycloheximide appeared to have no effect on IFN--y actions on EC.
These data raised the possibility that IFN-a or IFN-fl, induced by TNF or LT,
could mediate the actions of TNF and LT on MHC antigen expression. Here
we report that the actions of TNF and LT can be clearly distinguished from
those of IFN-a/# by examining the effects of these cytokines in the presence of
IFN-y. Specifically, LT and TNF act synergistically with IFN-y to enhance class
I MHC expression and do not significantly affect IFN-y-mediated class 11
induction, whereas IFN-a and IFN-,B are, at most, additive with IFN-y for class
I enhancement and strikingly inhibit the actions of IFN-y on class 11 expression.
In addition, LT or TNF can further enhance the expression of MHC antigens
induced by optimal levels of IFN-a or IFN-#. These new data make it seem
highly unlikely that LT or TNF regulate MHC antigen expression in EC by
inducing the synthesis of IFN-a or IFN-,#. Finally, experiments with rIL-6
(previously called 26-kD protein, IFN-R2 or B cell stimulating factor 2) do not
support the alternative hypothesis (18, 19) that this cytokine mediates the actions
of LT or TNF upon MHC expression in human EC since our IL-6 preparation
has no detectable effect on the levels of MHC antigen expression. We conclude
that there are at least three different classes of regulatory cytokines, LT/TNF,
IFN-a/,0, and IFN-y, each of which has distinct effects upon EC expression of
MHC antigens .
Materials and Methods
Human EC, isolated by collagenase treatment from umbilical vein segments, were
pooled (two to six donors) and serially subcultured using conditions described elsewhere
(20, 21). Selected experiments, where indicated, were performed with EC cultured from
a single umbilical vein segment (i.e., derived from one donor). All cultures in these
experiments were used between passage level 3 and 8. Cytokines, expressed as products
of recombinant cDNA clones or genes, were added to the cultures in complete standard
medium (Medium 199; Biofluids, Rockville, MD) supplemented with 20% FCS, glutamine,
antibiotics (all from Gibco Laboratories, Grand Island, NY), endothelial cell growth
supplement (50 Ag/ml; Collaborative Research, Lexington, MA), and porcine intestinal
heparin (100 Ag/ml, Sigma Chemical Co., St. Louis, MO) at the final concentrations
indicated. The specific recombinant cytokine preparations used in these studies included
TNF (expressed in Escherichia coli and purified to 2.5 X 10' U/mg in L929 cytotoxicity
assays, reference 22), LT (cDNA cloned from RPMI 1788 cells and expressed in Chinese
hamster ovary cells, partially purified to a concentration of 1 .5 X 105 U/ml in L929
cytotoxicity assays), IFN-1S (expressed in E. coli and purified to 108 U/mg, antiviral activity,
reference 23), IFN-y (cDNA expressed in Chinese hamster ovary cells, partially purified
to a concentration of 2 X 105 U/ml antiviral activity, reference 24), and IL-6 (cDNA
expressed in yeast, partially purified to a concentration of 8 .7 X 105 U/ml in B cell
stimulating factor 2 assays, reference 25). In addition, we obtained IL-la (2 .5 X 10'
U/mg in thymocyte costimulation assays) and IL-1,B (5 X 10' U/mg in thymocyte costim-
ulation assays) as gifts of Dr. Alan Shaw (Biogen, Geneva, Switzerland), and IFN-a (108
U/mg antiviral activity, consensus sequence), purchased from Amgen (Thousand Oaks,
CA). It should be noted that our preparations of LT and IFN-y were expressed in
mammalian cells and the preparation of IL-6 was expressed in a yeast system, resulting in
glycosylated molecules. All of the cytokines used in these studies (except IL-6, for which
specific antiserum is not available) could be neutralized by appropriate specific antisera
and were unaffectedin their endothelial-directed actions by 50 Ag/ml polymyxin B sulfate
(Sigma Chemical Co.).
Surface expression of MHC antigens was quantitated by indirect immunofluorescence796
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using a FACS Analyzer (Becton Dickinson & Co ., Mountain View, CA). Staining was
performed as previously described (10) . mAbs used were W6/32 (26) for HLA-A,B
antigens and LB3.1 (27) for HLA-DR antigens ; results with these antibodies were
confirmed with BBM.1 (28) (reactive with 02 microglobulin) and L243 (29) (purchased
from Becton Dickinson&Co., reactive with HLA-DR), respectively. Backgrounds for the
staining were determined with nonbinding isotype-matched controls . Second antibody
was a FITC-conjugated rabbit anti-mouse Ig serum (ICN Biochemicals, Cleveland, OH) .
Specific mRNA transcript levels for HLA-DR a chain were determined by Northern
blotting on nylon membranes (GeneScreen ; New England Nuclear, Boston, MA), using
cytoplasmic RNA prepared by methodsdescribed elsewhere (12) . The specific probe used
was a 0.6-kb Pst I fragment of an HLA-DR acDNA clone (containing the a2 conserved
domain); the complete cDNA (DB10) was a gift of Dr . Jack Strominger, Harvard
University, Cambridge, MA . The probe was labeled by random oligonucleotide priming
and blots were washed to a stringency of 0.5X standard sodium citrate, 1.0% SDS at
65°C . The specificity of the hybridization was confirmed by the size of the relevant
transcript (1 .3 kb for DR-a), based on comparisons to end-labeled Hind III a phage
markers, electrophoresed, and blotted in parallel .
Results
The effects of cytokines upon EC expression ofMHC antigens were examined
by indirect immunofluorescence and FACS quantitation . As reported previously,
EC express class I antigens but not class II antigens under standard culture
conditions (9) . The surface density of class I antigens is quite homogenous,
forminga tight log normal distribution, despite the fact that ourEC cultures are
derived from pooled donors . As a consequence of this homogeneity, it is reason-
able to represent the population by the modal fluorescence (determined by the
position of the peak channel for data expressed in the histogram mode of the
FACS analyzer) . In Fig. 1, the difference between the modal fluorescence of
FIGURE 1 .
￿
Modulation ofclass IMHC an-
tigen expression by various cytokines with
or without IFN-.y . Expression was quanti-
tated after 24 hoftreatment at the indicated
concentrations . Scale represents relative
modal fluorescence of W6/32 staining, de-
fined as net modal fluorescence ofcytokine-
treated sample in arbitrary units divided by
net modal fluorescence of control-treated
sample . Net modal fluorescence is deter-
mined by converting the difference in
modal channel numbers between W6/32
staining and staining with an irrelevant, iso-
type-matched control from a logarithmic to
a linear fluorescence scale . One of five sim-
ilar experiments .TABLE I
SynergyofLTandIFN-y on Surface Expression ofClass IMHC
Antigens (Relative W6/32Modal Fluorescence)
LAPIERRE ET AL .
￿
797
One ofnine similar experiments from pooled EC cultures ; similar results
were also obtained with two single donor EC cultures . Relative W6/32
modal fluorescence was as defined as in Fig. 1.
* 72 h of continuous treatment.
TABLE II
Effect ofLT on IFNModulation ofSurface Expression of Class I
Antigens (Relative W6/32Modal Fluorescence)
One of five similar experiments performed with pooled EC cultures ;
results of IFN-# and LT were also confirmed in two experiments with
single donorEC cultures . Modal fluorescence was as defined as in Fig . 1 .
* 24 h of continuous treatment .
W6/32 staining for class I antigens and that of isotype-matched irrelevant
antibody is normalized to a relative fluorescence of 1 .0 . As can be seen in the
toppanel (hatched bars), IFN-aand, to a lesser extent,TNFcause a concentration-
dependent elevation of class I MHC antigens at 24 h, whereas IL-la does not;
similarly, in the lower panel (hatched bars) IFN-# and, to a lesser extent, LT
cause a concentration-dependent elevation of class I MHC antigens, whereas IL-
I# does not . In both panels, an optimal concentration (200 U/ml) of IFN-y by
itself (top line, black bars)causes an elevation of class Iexpression . The interesting
result (remaining black bars) is that TNF and LT appear to synergize with IFN-
y, whereas IFN-a and IFN-,B show a combined effect with IFN-y that is less than
additive . IL-1 species did not affect the actions of IFN-y in these experiments .
The synergy of LT with IFN-y is further illustrated in Table I, where at all
concentrations tested, the enhancement caused by combined mediators is essen-
tially the product of the actions of either mediator alone.
Interestingly, LT can also induce a further increase in class I MHC antigen
expression beyond that produced by an optimal concentration of IFN-,B (1,000
U/ml, Table II). This interaction is at least additive and may also be synergistic,
as shown in Table III.
An additional difference between LT and IFN-# is illustrated in Fig . 2. In this
experiment, the left hand FACS profiles show that neither LT nor IFN-,Q induce
expression of class II MHC antigens by themselves . The right hand panels show
that the maximally effective concentration of LT (100 U/ml) has little effect on
Mediator Without LT LT (100 U/ml)
None 1 .0 1.8
IFN-,B (1,000 U/ml) 4.5 7.6
IFN-y (200 U/ml) 4.2 7.0
IFN-,B + IFN-y 7.0 10.3
Mediator Without
IFN-y
IFN-y
(20 U/ml)
IFN-y
(200 U/ml)
None 1.0 4.4 8.9
LT (10 U/ml) 1.6 7.5 13.3
LT (100 U/ml) 2.2 10.0 18.9798
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TABLE III
Interactions ofLT and IFN-,B on Surface Expression of Class IMHC
Antigens (Relative W6132ModalFluorescence)
Oneof threesimilarexperiments. Fluorescence was as defined as in Fig. 1.
* 24 h of continuous treatment.
WITHOUT IFN-'Y
IFN-T (2000/mll
0
0
0 1
101 102 103 101 102 103
FLUORESCENCE INTENSITY
NONE
LT(10U/mll
LT(1000/mD
LT(1000U/ml)
IFN-(3 (1000/mU
IFN-Q(1000U/mD
FIGURE 2. FACS analyses of class 11 MHC
antigen expression on cytokine-treated EC
after 48 h of treatment. The solid lines show
staining of HLA-DR with antibody LB3.1 ; the
dotted lines show staining with an irrelevant
mouse myeloma protein. One of four similar
experiments.
the expression of HLA-DR induced by IFN-y, whereas IFN-,0, at its maximally
effective concentration (1,000 U/ml), is profoundly inhibitory. The positive
actions of LT and IFN-# in the presence ofIFN-y on class I expression on the
same samples (not shown) rule out the possibility that inhibition of class II
expression by IFN-,Q is due to toxicity. Other experiments (not shown) indicate
thatTNF, like LT, haslittle effect on IFN-y-mediated class II induction, whereas
IFN-a, like IFN-,3, is inhibitory. IL-Ia and IL-1,l have no effect on IFN-y
induction ofclass II (not shown). The distinction between LT and IFN-a on class
11 expression was confirmed by Northern blot analysis in the experiment shown
in Fig. 3; 100 U/ml LT was only minimally inhibitory, whereas 1,000 U/ml IFN-
,6 completely blocked the appearance of DRa mRNA caused by 200 U/ml IFN-
y in the control cultures.
Mediator* Without
IFN-#
IFN-#
(10 U/ml)
IFN-0
(100 U/ml)
IFN-#
(1,000 U/ml)
None 1.0 2.1 3.8 4.9
LT (1 U/ml) 1.4 2.9 5.1 6.5
LT (10 U/ml) 2.2 4.1 6.6 10.7
LT (100 U/ml) 1.9 5.3 8.7 9.4LAPIERRE ET
Discussion
AL .
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FIGURE 3 . Northern blot, quantifying
HLA-DR mRNA levels after 24 h continu-
ous treatment with cytokines. Each lane con-
tained 30 jug/ml cytoplasmic RNA, pre-
pared from EC treated as follows : (A) no
cytokine ; (B) IFN-y (200 U/ml) ; (C) LT
(100 U/ml) ; (D) LT (100 U/ml), and IFN-
((200 U/ml); (E) IFN-,B (1,000 U/ml) ; and
(F) IFN-,B (1,000 U/ml) and IFN-y (200
U/ml). FACS analysis of a sample of the
cells used for RNA extraction confirmed
that, in this experiment, LT and IFN-,B each
further enhanced IFN-y-mediated increases
in class I expression, whereas only IFN-,B
inhibitedIFN-y-mediated class II induction
(not shown). One of two similar experi-
ments .
TABLE IV
Effect ofIL-6 on Surface Expression ofClass IMHCAntigens
(Relative W6/32 Modal Fluorescence)
Oneof two similar experiments. Fluorescence as defined as in Fig. 1 .
* 24 h continuous treatment .
Previous studies (16) had suggested that TNF (and by implication LT) elevates
class I transcripts by induction of an intermediary protein . Since the functional
effects of LT and TNF have now been shown to be distinct from those of IFN-
af, it seems highly unlikely that the actions ofTNF or LT on MHC expression
in EC could be mediated by stimulating the secretion of IFN-a or IFN-,l . It has
been alternatively suggested that IL-6 (referred to by some investigators as IFN-
02) mightserve as theautocrine or paracrine second message forTNFmodulation
ofMHC expression (18, 19) . To test this possibility, a recombinant preparation
of IL-6 was compared with the actions of LT . As shown in Table IV, even at
concentrations of 2 .5 ug/ml (equivalent to 8.7 x 10' U/ml of B cell stimulating
factor 2 activity), our preparation of IL-6 does not mimic the actions of LT on
EC ; i.e ., it neither directly enhances class I MHC expression nor synergizes with
IFN-y to produce a further increase of class I.
The data presented in this report functionally distinguish the actions of LT
and TNF from those of IFN-a and IFN-,8 in assays of MHC modulation on
cultured EC. Specifically, although all four cytokines act to enhance EC expres-
sion of class I MHC antigens without inducing class II antigens, TNF and LT
act in synergy with IFN-y on class I, whereas IFN-a and IFN-,6 act at most with
additivity . Furthermore, LT and TNF have little effect on class II expression
induced by IFN-y whereas IFN-a and IFN-0 are profoundly inhibitory . Finally,
Mediator* Without IFN-- t
IFN-y
(200 U/ml)
None 1 .0 4.7
LT (100 U/ml) 1 .7 11 .0
IL-6 (8.7 x 10' U/ml) 1 .1 4.4800
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LT or TNF cause further increases in class I antigen expression on cells already
optimally stimulated by IFN-a or IFN-ft (i.e., with a concentration of cytokine
greater than the maximally effective level). Collectively, these observations
suggest that there are at least three separate classes of MHC modulating cyto-
kines: TNF/LT; IFN-a/a; and IFN-y. We propose that the net regulatory effect
on EC expression of MHC antigens in vivo will depend upon the quantity and
timing of cytokine generation in situ.
The responses of EC to cytokines should be considered in the context of what
is known regarding the responses of other cell types. In EC, we have seen little
effect of LT or TNF on EC expression of class II antigens, and certainly no
positive effect. However, certain tumor cell lines appear to express class II
molecules directly in response to these cytokines (30, 31). Furthermore, although
IFN-y is a sufficient signal to induce class II expression in EC as in most other
cell types (32), recent studies have shown that TNF or LT serve as necessary
cofactors with IFN-y for class II induction on pancreatic isletcells (33). It remains
to be seen if the EC pattern is the norm or one of several common variants.
The comparison of TNF or LT with the IFN family extends beyond the issue
of MHC regulation. Like the IFNs, TNF and LT are growth inhibitory (34, 35)
and produce an antiviral state (36, 37). Since the actions of TNF (and presumably
LT) on the MHC appear to involve synthesis of a protein (i.e., the mRNA
increase is blocked by cycloheximide). IFN-a or -Q were considered as potential
second signals. Our inability to find IFN-,l mRNA induction in EC or dermal
fibroblasts treated with TNF (16) was confirmed by others who found, instead,
the induction of IL-6 (18), originally called IFN-N2 (38) or 26-kD protein (25),
or B cell stimulating factor 2 (39). It has been proposed that IL-6 mediates the
actions of TNF (and presumably LT) on MHC antigen expression (19). Our
initial experiments with a recombinant preparation of IL-6, biologically active as
a B cell stimulating factor, are not consistent with this hypothesis in that IL-6
did not serve to regulate MHC expression in human EC . It remains to be
determined whether other preparations or forms of IL-6 can modulate MHC
expression, as there are reported discrepancies as to whether different prepara-
tions of this cytokine have antiviral activity (38, 40).
Our comparisons of LT and TNF with IFN-a and IFN-,8 have both biological
and clinical implications. For example, we would predict that TNF or LT will
augment the immune enhancing actions of IFN-y. In the specific context of EC
functions, TNF or LT would dramatically boost the IFN-y effect on expression
of class I MHC antigens, rendering EC more potent at interacting with cytolytic
T lymphocytes (8). Furthermore, the coincident induction of membrane-associ-
ated IL-1 by TNF or LT (41) and of class II MHC antigens by IFN-y may show
"biological synergy" in promoting the activation of helper T lymphocytes. Since
the same T cells that produce IFN-y also appear to produce LT (42), the
coincident exposure of EC to both cytokines appears quite likely. In contrast, we
would predict that IFN-a and IFN-,8, which have also been found to inhibit IFN-
y-induced class II antigen expression on murine mononuclear phagocytes (43-
45), will be immunosuppressive. With specific regard to EC functions, the
inhibition of class II MHC expression may, in turn, inhibit the recruitment of
antigen-specific helper T lymphocytes and thus block the development of im-LAPIERRE ET AL.
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mune inflammation. The signals required for IFN-a and IFN-a secretion (e.g.,
dsRNA, virus infection, etc.) are quite distinct from those that elicit IFN-y and
LT (e.g., antigen, Tcell mitogens, etc.), and the inhibitory effects ofIFN-a and
IFN-# may not normally come into play in an immune response to antigen.
However, the recent use of recombinant cytokines in various clinical settings
(e.g., treatment of tumors or of viral infections) may have to be reevaluated in
terms ofwhether an immunostimulatoryagent (as inacquired immunodeficiency
syndrome) or immunoinhibitory agent (as in a transplant recipient) would be
preferable.
Summary
Recombinant preparations ofTNF and lymphotoxin (LT) increase the expres-
sion of class I MHC antigens on cultured human endothelial cells (EC) without
inducing expression of class II antigens. These actions are similar to those of
rIFN-a or rIFN-,l. However, TNF and LT differ from IFN-a/# in that the
former synergize with IFN-y for class I regulation whereas the latter do not.
Furthermore, LT or TNF do not affect IFN-y-mediated class II induction at
optimal class I inducing concentrations (100 U/ml), whereas IFN-a and IFN-0
(at their optimal concentrations of 1,000 U/ml) are strikingly inhibitory. LT and
TNF also can further increase expression of class I antigens on cells already
maximally stimulated by IFN-a or IFN-0. A recombinant preparation of IL-6
(formerlycalled 26-kDprotein, IFN-N2,or Bcell stimulating factor 2)was without
effect on class I expression in EC. These data make it seem unlikely that the
actions ofLT or TNF on EC expression ofMHC antigensare mediated through
autocrine or paracrine production of IFN-a, IFN-,B or IL-6. More importantly,
they suggest that LT or TNF are more likely to be immunostimulatory, whereas
IFN-a or IFN-,B are more likely to be immunoinhibitory in vivo, a consideration
ofpotential relevance for cytokine administration to various patient populations.
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